Advertisement


Heather Wakelee, MD, on NSCLC: IMpower010 Survival Results After Long-Term Follow-up of Atezolizumab vs Best Supportive Care

2024 ASCO Annual Meeting

Advertisement

Heather Wakelee, MD, of Stanford University Medical Center, discusses phase III findings showing that the disease-free survival benefit with adjuvant atezolizumab continues to translate into a positive overall survival trend vs best supportive care in patients with stage II–IIIA non–small cell lung cancer (NSCLC). These results further support the use of adjuvant atezolizumab in PD-L1–selected populations, according to Dr. Wakelee (LBA8035).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
IMpower010, which looked at adjuvant atezolizumab for patients with completely resected early stage non-small cell lung cancer, we presented the long-term final disease-free survival as well as the second interim overall survival data, now with over 60 months of follow-up. The study had a complex hierarchical statistical design such that first group were those with PD-L1 expression stage 2 to 3A, next group, all stage 2 to 3A, then all comers, including about 12% of patients with 1B, and only if all three of those were met could we formally test overall survival. As was seen in the first interim analysis, the second interim now with the final disease-free survival in that first group with PD-L1 expression stage 2 to 3A remains robust with a hazard ratio of 0.7, translating into nearly a 30-month difference in disease-free survival. In the second group, when we look at all stage 2 to 3A, continue to see a disease-free survival benefit, which does reach statistical significance, hazard ratio of 0.85. But when we bring in that stage 1B, that drops to... Sorry, that was 0.83. ... 0.85, when we bring in that other group, no longer statistically significant. So overall survival could not be formally tested, but we do continue to see this robust disease-free survival benefit, particularly in those with PD-L1 expression. And when we look at those with the highest PD-L1 expression, greater than 50%, that disease-free survival benefit hazard ratio was 0.48. We haven't reached the median for that group of patients. And, in that group, the overall survival hazard ratio was 0.47. However, we can't formally statistically test that because of the way the trial is designed. So in conclusion, when we look at this final disease-free survival result and second interim overall survival result from IMpower010, we do continue to see robust clinical benefit for patients who have gone through surgical resection with early stage lung cancer, stage 2 to 3A, where their tumor expresses PD-L1 expression. And we do believe this continues to be a very reasonable treatment option for that subgroup of patients where there is PD-L1 expression, particularly in those with the highest PD-L1 expression of greater than 50%.

Related Videos

Lymphoma

Peter Riedell, MD, on DLBCL: Expert Commentary on the DEB Study

Peter Riedell, MD, of The University of Chicago, discusses phase III results on the use of tucidinostat plus R-CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) with double expression of MYC and BCL2. The regimen appeared to improve event-free survival and complete response rates vs R-CHOP in the front-line setting. As this is an interim analysis, longer-term follow-up will be needed to better understand its impact, says Dr. Riedell.

Leukemia

Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Recruiting for the CELESTIAL-TNCLL Study

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses an ongoing phase III study of the BCL2 inhibitor sonrotoclax plus zanubrutinib vs venetoclax and obinutuzumab for patients with treatment-naive chronic lymphocytic leukemia. The investigators are recruiting internationally (see NCT06073821; Abstract TPS7087).

Multiple Myeloma

Claudio Cerchione, MD, PhD, on Staging Multiple Myeloma: New Findings on FDG PET/CT Scans and Whole-Body MRI

Claudio Cerchione, MD, PhD, of Italy’s Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, discusses preliminary findings from a prospective trial suggesting that by adding whole-body MRI to fludeoxyglucose-18 (FDG) PET/CT scans, clinicians may detect bone lesions earlier and more accurately in patients with either newly diagnosed or relapsed multiple myeloma, thus translating into potentially better outcomes (Abstract 7512).

Gynecologic Cancers

Yukio Suzuki, MD, PhD, on Endometrial Cancer: Long-Term Survival Outcomes With Hormonal Therapy in Reproductive-Age Patients

Yukio Suzuki, MD, PhD, of Columbia University College of Physicians and Surgeons, discusses data showing that reproductive-age patients with early-stage endometrial cancer who use fertility-preserving hormonal therapy seemed to have good overall survival after a 10-year follow-up (Abstract 5508).

Skin Cancer

Axel Hauschild, MD, on Melanoma: Findings From the PIVOTAL Trial of Daromun vs Surgery

Axel Hauschild, MD, of Germany’s University of Kiel and University Hospital Schleswig-Holstein, discusses phase III study results on neoadjuvant intralesional daromun vs immediate surgery for patients with fully resectable, locally advanced melanoma (Abstract LBA9501).

Advertisement

Advertisement




Advertisement